Begin main content

Drug Reimbursement Recommendation

August 29, 2019
Today, CADTH has issued final recommendations for: Daratumumab (Darzalex) in combination with bortezomib, melphalan and prednisone for newly diagnosed multiple myeloma Funding Request: In combination with bortezomib, melphalan and prednisone, for the treatment of patients with newly diagnosed multiple myeloma who are not suitable for autologou...

Call for Patient Input and Clinical Experts: Mayzent and brolucizumab

August 28, 2019
CADTH has received the following notice(s) of pending drug submission(s). Brand name Mayzent TBC Generic name siponimod brolucizumab Manufacturer Novartis Pharmaceuticals Canada Inc. Novartis Pharmaceuticals Canada Inc. Indication(s) For the treatment of patient with secondary progressive...

Call for Feedback: Drugs for Osteoporosis

August 28, 2019
A document related to the project entitled Drugs for Osteoporosis is now available for feedback from all interested stakeholders. Project Call for Feedback Feedback Due By Drugs for Osteoporosis 2019-08-28 2019-09-12 Consultation Document Product Type Submit Stakeholder Feedback Included Stu...

CADTH Pharmaceutical Reviews Update — Issue 10

August 22, 2019
See CADTH Pharmaceutical Reviews Update — Issue 10 for important news and information regarding CADTH’s drug review programs. Highlights from this issue include: an extension of the feedback period on the ongoing consultations an updated procedure for implementation-phase clinical panels the upcoming announcement of a pilot p...